Clinical trials: B-Cell Lymphoproliferative Disorder
Non-Hodgkin Lymphoma
Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma
This is a randomized, open label, multicenter phase III trial comparing the efficacy, safety, and tolerability of tisagenlecleucel to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of…
- Trial name
- BELINDA (NCT03570892)
- Testing
- Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy, Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
- Where
- 67 sites in United States, Australia and 16 more
- Volunteers
- 330 people
- Sponsor
- Novartis Pharmaceuticals
Lymphoma, Large B-Cell, Diffuse
A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)
This is a multicenter China-only study to investigate the PK, efficacy and safety of SC rituximab versus IV rituximab, both in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) in previously untreated…
- Trial name
- NCT04660799
- Testing
- Rituximab IV, Rituximab SC, Cyclophosphamide
- Where
- 8 sites in China
- Volunteers
- 50 people
- Sponsor
- Hoffmann-La Roche
B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia
This is a Phase II, open-label, prospective, multicenter study to evaluate the efficacy and safety of subcutaneously administered alemtuzumab (CAMPATH, MabCampath) as therapy for patients with relapsed or refractory B-CLL who…
- Trial name
- NCT00328198
- Testing
- Alemtuzumab
- Where
- 21 sites in United States, Belgium and 4 more
- Volunteers
- 86 people
- Sponsor
- Genzyme, a Sanofi Company
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies
This phase I trial studies the side effects and best dose of genetically modified T-cell therapy in treating patients with receptor tyrosine kinase-like orphan receptor 1 positive (ROR1+) chronic lymphocytic leukemia (CLL)…
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Triple-Negative Breast Carcinoma
- Trial name
- NCT02706392
- Testing
- Laboratory Biomarker Analysis, ROR1 CAR-specific Autologous T-Lymphocytes
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Fred Hutchinson Cancer Center
Non-Hodgkin's Lymphoma
A Study of Dulanermin in Combination With Rituximab in Subjects With Follicular and Other Low Grade, CD20+, Non-Hodgkin's Lymphomas
This Phase Ib/II, open-label, multicenter trial is designed to evaluate the safety, pharmacokinetics, and efficacy of dulanermin when combined with rituximab in subjects with follicular, CD20+, B-cell Non-Hodgkin's Lymphoma (NHL)…
- Trial name
- NCT00400764
- Testing
- Dulanermin, Rituximab
- Volunteers
- 72 people
- Sponsor
- Genentech, Inc.
Non-Hodgkin's Lymphoma
A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
This study will evaluate the safety, efficacy, and pharmacokinetics of induction treatment with obinutuzumab, polatuzumab vedotin, and venetoclax in participants with relapsed or refractory FL, and with rituximab, polatuzumab…
- Trial name
- NCT02611323
- Testing
- Obinutuzumab, Rituximab, Polatuzumab Vedotin
- Where
- 23 sites in United States, Australia and 1 more
- Volunteers
- 133 people
- Sponsor
- Hoffmann-La Roche
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myeloid, Acute
Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604)
A bone marrow transplant, which is a type of stem cell transplant, is a treatment option for people with leukemia or lymphoma. Recently, stem cell transplants using umbilical cord blood have become a treatment option for people…
- Conditions
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myeloid, Acute, Burkitt Lymphoma, Lymphoma, B-Cell
- Trial name
- NCT00864227
- Testing
- Hematopoietic Umbilical Cord Blood Stem Cell Transplantation, GVHD prophylaxis
- Where
- 16 sites in United States
- Volunteers
- 54 people
- Sponsor
- Medical College of Wisconsin
AIDS-Related Plasmablastic Lymphoma, AIDS-Related Primary Effusion Lymphoma
Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas
This partially randomized phase I/II trial studies the side effects and the best dose of vorinostat when given together with combination chemotherapy and rituximab to see how well it works compared to combination chemotherapy…
- Conditions
- AIDS-Related Plasmablastic Lymphoma, AIDS-Related Primary Effusion Lymphoma, Ann Arbor Stage I Diffuse Large B-Cell Lymphoma, Ann Arbor Stage I Grade 3 Follicular Lymphoma
- Trial name
- NCT01193842
- Testing
- Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide
- Where
- 35 sites in United States
- Volunteers
- 107 people
- Sponsor
- National Cancer Institute (NCI)
Acute Lymphoid Leukemia (ALL), Acute Myeloid Leukemia (AML)
Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors
This study is being done to learn whether a new method to prevent rejection between the donor immune system and the patient's body is effective.
- Conditions
- Acute Lymphoid Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), Hodgkin Lymphoma
- Trial name
- NCT03615105
- Testing
- Hyperfractionated total body irradiation, Thiotepa, Cyclophosphamide
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Chronic Myeloproliferative Disorders, Leukemia
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
RATIONALE: A peripheral stem cell transplant or an umbilical cord blood transplant from a donor may be able to replace blood-forming cells that were destroyed by chemotherapy or radiation therapy.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00281879
- Testing
- anti-thymocyte globulin, filgrastim, busulfan
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- OHSU Knight Cancer Institute
Prolymphocytic Leukemia, Recurrent Adult Hodgkin Lymphoma
Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma
This phase I/II trial studies how well autologous stem cell transplant followed by donor stem cell transplant works in treating patients with lymphoma that has returned or does not respond to treatment.
- Conditions
- Prolymphocytic Leukemia, Recurrent Adult Hodgkin Lymphoma, Recurrent Childhood Hodgkin Lymphoma, Recurrent Childhood Non-Hodgkin Lymphoma
- Trial name
- NCT00005803
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation, Carmustine
- Where
- 5 sites in United States, Germany
- Volunteers
- 76 people
- Sponsor
- Fred Hutchinson Cancer Center
Recurrent Chronic Lymphocytic Leukemia
Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia
This phase I/II trial studies the side effects and best dose of lenalidomide when given together with R-(-)-gossypol acetic acid and to see how well they work in treating patients with B-cell chronic lymphocytic leukemia (B-CLL)…
- Trial name
- NCT01003769
- Testing
- Lenalidomide, R-(-)-Gossypol Acetic Acid, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Mayo Clinic
Recurrent Adult Lymphoblastic Lymphoma, Recurrent B Acute Lymphoblastic Leukemia
Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
This phase Ib/II trial studies the effects of tagraxofusp and low-intensity chemotherapy in treating patients with CD123 positive acute lymphoblastic leukemia or lymphoblastic lymphoma that has come back (relapsed) or does not…
- Conditions
- Recurrent Adult Lymphoblastic Lymphoma, Recurrent B Acute Lymphoblastic Leukemia, Recurrent T Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia
- Trial name
- NCT05032183
- Testing
- Cyclophosphamide, Cytarabine, Dexamethasone
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Lymphocytic Leukemia
Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
The primary objective of this study is to determine the preliminary efficacy of the combination of tirabrutinib and idelalisib with obinutuzumab in adults with relapsed or refractory chronic lymphocytic leukemia (CLL).
- Trial name
- NCT02968563
- Testing
- Tirabrutinib, Idelalisib, Obinutuzumab
- Where
- 14 sites in Germany
- Volunteers
- 35 people
- Sponsor
- Gilead Sciences
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)
This phase II MATCH treatment trial identifies the effects of afatinib in patients whose cancer has genetic changes called HER2 mutations.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439136
- Testing
- Afatinib Dimaleate
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma
Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
This phase I trial studies the side effects and best dose of iodine I 131 monoclonal antibody BC8 when given before autologous stem cell transplant in treating patients with Hodgkin lymphoma or non-Hodgkin lymphoma that has…
- Conditions
- Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
- Trial name
- NCT00860171
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Iodine I 131 Monoclonal Antibody BC8, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Fred Hutchinson Cancer Center
Chronic Lymphocytic Leukemia
Lenalidomide Following Fludarabine/Rituximab (FR) in Untreated Chronic Lymphocytic Leukemia (CLL)
This study is for patients with chronic lymphocytic leukemia (CLL) who have not yet received any treatment for their disease. Current therapy for this disease includes the use of combination chemotherapy regimens containing…
- Trial name
- NCT00860457
- Testing
- Rituximab, Fludarabine, Lenalidomide
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Georgetown University
Chronic Lymphocytic Leukemia
Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression Analysis
Background: Combined therapy with rituximab and fludarabine is the treatment of choice for advanced stage chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
- Trial name
- NCT00001586
- Testing
- Rituximab, Fludarabine phosphate, Leukemic or stroma cells
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia
Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas
This phase II trial studies how well pembrolizumab alone or with idelalisib or ibrutinib works in treating patients with chronic lymphocytic leukemia or other low-grade B-cell non-Hodgkin lymphomas that have returned after a…
- Conditions
- Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Recurrent Grade 1 Follicular Lymphoma
- Trial name
- NCT02332980
- Testing
- Ibrutinib, Idelalisib, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 65 people
- Sponsor
- Mayo Clinic
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
An Open-label Extension Study in Patients 65 Years or Older with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (Ibrutinib versus Chlorambucil)
- Trial name
- NCT01724346
- Testing
- Ibrutinib, Next-line ibrutinib
- Where
- 88 sites in United States, Australia and 14 more
- Volunteers
- 269 people
- Sponsor
- Pharmacyclics LLC.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.